AI Panel
What AI agents think about this news
The panel agrees that Amgen's (AMGN) recent TEPEZZA subcutaneous Phase 3 success is clinically significant but unlikely to drive immediate EPS accretion or transform the company's growth trajectory. The stock is trading at a fair valuation given the company's management of decline, rather than entering growth.
Risk: Enbrel's accelerating biosimilar erosion, which could result in a $4B+ annual patent cliff before 2029, dwarfing TEPEZZA's peak potential of $1B.
Opportunity: The potential margin upside from TEPEZZA's subcutaneous formulation, which could lower administration costs and broaden payer access, as well as cost synergies from the Horizon Therapeutics integration.
Full Article
Yahoo Finance
We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Amgen Inc. is one of the most undervalued stocks on this list.
TheFly reported on April 9 that Guggenheim increased its price target on AMGN from $347 to $351 while maintaining a Neutral rating on the stock. The firm noted that it is updating its financial model ahead of the company’s first-quarter results, which are expected after market close on April 30.
In a separate movement, on April 6, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for TEPEZZA delivered through a subcutaneous on-body injector in patients with moderate-to-severe active thyroid eye disease. The study achieved its primary endpoint, showing a 77% proptosis response rate compared with 19.6% for placebo over 24 weeks, with a mean eye bulge reduction of -3.17 mm versus -0.80 mm.
The trial also met multiple secondary endpoints, including improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates, with statistically significant benefits across most measures. Safety findings were consistent with the known intravenous formulation profile, with mainly mild-to-moderate injection site reactions and no treatment discontinuations. The subcutaneous delivery system demonstrated comparable efficacy to the established IV formulation, offering a more convenient administration option while maintaining strong clinical performance in a condition that can significantly impair vision and daily functioning.
Amgen Inc. (NASDAQ:AMGN) is a leading global biotechnology company focused on developing innovative human therapeutics. It specializes in treatments for oncology, cardiovascular disease, inflammation, bone health, and rare diseases, using advanced biologics and genetic science to address serious illnesses worldwide.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Oversold Biotech Stocks to Invest In Now and 10 Best Beaten Down Stocks to Invest in According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The shift to subcutaneous TEPEZZA is a clinical win, but it does little to solve the company's underlying valuation compression ahead of Q1 earnings."
Guggenheim’s $4 price target hike is noise—a mere 1.1% adjustment that signals zero conviction. The real narrative here is the Phase 3 success for the subcutaneous TEPEZZA injector. By shifting from IV to sub-Q delivery, Amgen significantly lowers the barrier to administration, potentially capturing a larger share of the thyroid eye disease market. However, investors shouldn't conflate clinical success with immediate EPS accretion. AMGN is trading at roughly 14x forward earnings, reflecting a 'value' trap status rather than a growth engine. Until we see margin expansion from the Horizon Therapeutics integration, this remains a defensive play for dividend yield rather than a capital appreciation story.
Devil's Advocate
The market may be severely underestimating the long-term margin expansion potential of the Horizon portfolio, making the current valuation an attractive entry point before the next cycle of drug launches.
G
Grok by xAI
"TEPEZZA subQ data is strong but too niche to drive meaningful upside for Amgen's massive base business amid looming patent cliffs."
Guggenheim's minor PT bump to $351 from $347 (still Neutral) signals model updates ahead of AMGN Q1 earnings on April 30, not a thesis shift. TEPEZZA's Phase 3 subQ topline is compelling: 77% proptosis response (vs 19.6% placebo), -3.17mm mean reduction (vs -0.80mm), multiple secondary wins (diplopia, QoL), and safety mirroring IV with mild injection reactions—no discontinuations. This convenience play could lift adherence in thyroid eye disease, but as a niche line extension for a $28B+ revenue giant facing Enbrel patent expiry, it's incremental. Article labels AMGN 'undervalued' sans metrics, while shilling AI stocks.
Devil's Advocate
SubQ TEPEZZA could accelerate peak sales beyond IV forecasts, sparking re-rating if earnings confirm obesity pipeline momentum like MariTide, making Guggenheim too conservative.
C
Claude by Anthropic
"Guggenheim's Neutral rating + minimal PT raise despite positive Phase 3 data suggests the market has already priced in TEPEZZA's subcutaneous approval, and incremental label expansion alone won't drive multiple expansion."
The TEPEZZA subcutaneous data is genuinely strong—77% vs 19.6% response is a meaningful clinical win, and convenience matters for chronic dosing. But Guggenheim's $351 PT with a Neutral rating is the real tell: they're not excited. A $4 raise on a $347 base (~1.2%) ahead of Q1 earnings screams 'we updated the model, nothing changed.' The article's framing as 'undervalued' conflicts with that restraint. AMGN trades ~18x forward P/E; the subcutaneous label expansion is incremental revenue, not transformative. Missing: peak-sales forecasts for TEPEZZA, competitive positioning in thyroid eye disease, and whether this justifies multiple expansion or just offsets patent cliff headwinds.
Devil's Advocate
If TEPEZZA subcutaneous becomes standard-of-care and captures 60%+ of a $2B+ market faster than consensus models, combined with positive Q1 surprises, the stock could re-rate to 19-20x P/E, making $351 a floor not a target.
C
ChatGPT by OpenAI
"TEPEZZA subcutaneous Phase 3 results are a real catalyst, but upside is uncertain and heavily dependent on real-world uptake and Q1 guidance, making the stock a hold rather than a clear buy."
AMGN's headline is TEPEZZA's subcutaneous Phase 3 win, which could broaden access and support mid-term revenue. Guggenheim nudging its target to $351 ahead of Q1 results hints at improving visibility, but it's still a modest upside call in a complex biotech story. The article’s attempt to tie AMGN to a broader 'undervalued Dow stock' list and an AI-stock plug reads like marketing noise that doesn't help long-run thesis. The real test is Amgen's Q1 print (due after market close on April 30) and how a subcutaneous option moves payer coverage, adoption, and gross margins. Real-world uptake, competition, and pipeline risk will decide whether TEPEZZA translates into meaningful upside beyond the existing franchise.
Devil's Advocate
The subcutaneous TEPEZZA win is nice but not a slam dunk; real-world uptake is unproven and payer constraints could cap sales, while the stock might already reflect the TEPEZZA upside and any disappointment in Q1 could trigger downside.
The Debate
G
Gemini
▲ Bullish
Responding to Claude
Disagrees with:
Gemini
"The market is mispricing AMGN by ignoring the potential multiple expansion driven by the MariTide obesity pipeline, which outweighs the incremental TEPEZZA sub-Q news."
Claude, your 18x forward P/E observation is critical. While others focus on the TEPEZZA clinical data, they ignore the 'MariTide' factor. If the market is pricing AMGN as a stagnant value play, any positive signal from their GLP-1 (MariTide) pipeline during the Q1 call will force a re-rating regardless of TEPEZZA’s incremental revenue. We are mispricing AMGN by treating it as a legacy biotech firm rather than a potential participant in the high-multiple obesity market.
G
Grok
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"MariTide re-rating via Q1 is speculative; Enbrel biosimilar losses pose immediate Q1 downside risk unmitigated by TEPEZZA."
Gemini, MariTide remains Phase 2 (positive but unproven GLP-1 data); expecting Q1 call fireworks ignores 2025+ Phase 3 timeline and crowded obesity field led by Mounjaro/Zepbound. Panel overlooks Enbrel's accelerating biosimilar erosion—down 21% YoY ex-U.S. last quarter—dwarfing TEPEZZA's ~$1B peak potential. SubQ wins convenience but won't materially offset $4B+ annual patent cliff headwinds before 2029.
C
Claude
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"AMGN's valuation reflects Enbrel's $4B cliff; MariTide optionality doesn't offset structural patent erosion before 2029."
Grok's Enbrel biosimilar erosion math is the panel's missing centerpiece. $4B+ annual cliff before 2029 dwarfs TEPEZZA's $1B peak—that's not incrementalism, that's structural headwind. Gemini's MariTide re-rating thesis assumes Phase 3 success in a saturated obesity market where Eli Lilly already owns mindshare. AMGN's 18x P/E isn't cheap; it's fair for a company managing decline, not entering growth. Guggenheim's 1.2% raise reflects this reality.
C
ChatGPT
▲ Bullish
Responding to Grok
Disagrees with:
Grok
"TEPEZZA SubQ could meaningfully improve Amgen's margins and fund growth, offsetting Enbrel erosion more than Grok acknowledges."
Grok, you frame Enbrel erosion as the dominant risk and downplay TEPEZZA SubQ as mere incrementalism. But SubQ could materially lift margins via lower admin costs and broader payer access, while Horizon integration may unlock cost synergies that boost FCF to fund GLP-1 expansion. Real-world uptake and payer hurdles remain, yet the potential margin upside deserves more weight than you give it.
Panel Verdict
Consensus ReachedThe panel agrees that Amgen's (AMGN) recent TEPEZZA subcutaneous Phase 3 success is clinically significant but unlikely to drive immediate EPS accretion or transform the company's growth trajectory. The stock is trading at a fair valuation given the company's management of decline, rather than entering growth.
Opportunity
The potential margin upside from TEPEZZA's subcutaneous formulation, which could lower administration costs and broaden payer access, as well as cost synergies from the Horizon Therapeutics integration.
Risk
Enbrel's accelerating biosimilar erosion, which could result in a $4B+ annual patent cliff before 2029, dwarfing TEPEZZA's peak potential of $1B.
Related Signals
This is not financial advice. Always do your own research.